THE People’s Health Forum is very concerned about the questionable study dubbed “Cost-Benefit Assessment (CBA) 2.0” on the impact of the proposed medicines price regulation (MPR) policy.
The policy was tabled by the Health Ministry (MOH) in collaboration with the Domestic Trade and Consumer Affairs Ministry and approved by the Cabinet in April 2019.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
